Radiopharm Theranostics Limited, a pioneering biotech company situated in Carlton South, Australia, has been making significant strides in the health care sector. Specializing in the development of radiopharmaceutical products, the company is dedicated to addressing high unmet medical needs through innovative diagnostic and therapeutic solutions. With a global customer base, Radiopharm Theranostics is at the forefront of advancing medical technology, offering hope and improved outcomes for patients worldwide.

As of October 8, 2025, the company’s shares were trading at a close price of 0.037 AUD on the ASX All Markets, reflecting a dynamic market presence. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of 0.042 AUD on December 8, 2024, and a low of 0.019 AUD on April 6, 2025. Despite these variations, the company’s market capitalization stands at a robust 87,503,151 AUD, underscoring its substantial impact and potential within the biotech industry.

Radiopharm Theranostics’ commitment to innovation is evident in its focus on developing cutting-edge radiopharmaceuticals. These products are designed to enhance the precision of diagnostic imaging and the efficacy of targeted therapies, thereby improving patient care and outcomes. By addressing areas of significant medical need, the company not only contributes to the advancement of health care but also positions itself as a leader in the biotech field.

The company’s strategic location in Carlton South, Australia, serves as a hub for its research and development activities. Here, a team of dedicated scientists and researchers work tirelessly to push the boundaries of medical science. Their efforts are aimed at creating products that can be used globally, reflecting Radiopharm Theranostics’ commitment to serving a diverse international clientele.

For those interested in learning more about Radiopharm Theranostics’ activities and offerings, the company maintains an informative website at www.radiopharmtheranostics.com . This platform provides insights into their latest developments, research initiatives, and the potential impact of their products on the health care landscape. Additionally, investors and stakeholders can engage with the company through its presence on the ASX All Markets, where they can track its financial performance and strategic direction.

In summary, Radiopharm Theranostics Limited continues to be a beacon of innovation in the health care sector. With its focus on developing radiopharmaceuticals for diagnostic and therapeutic uses, the company is not only addressing critical medical needs but also paving the way for future advancements in biotechnology. As it navigates the complexities of the global market, Radiopharm Theranostics remains committed to its mission of improving patient care and outcomes through scientific excellence and innovation.